论文信息 - Tau-targeting antibody therapies: too late, wrong epitope or wrong target? - 字舞流文

Tau-targeting antibody therapies: too late, wrong epitope or wrong target?

K. Duff | E. Jabbari

[1] Nikolaus R. McFarland,et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial , 2021, The Lancet Neurology.

[2] Sonja W. Scholz,et al. Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study , 2020, The Lancet Neurology.

[3] J. Trojanowski,et al. Characterization of tau binding by gosuranemab , 2020, Neurobiology of Disease.

[4] L. Buée,et al. A walk through tau therapeutic strategies , 2019, Acta Neuropathologica Communications.

[5] J. Hardy,et al. Variation at the TRIM11 locus modifies progressive supranuclear palsy phenotype , 2018, bioRxiv.

[6] A. Goldberg,et al. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling , 2015, Nature Medicine.

[7] D. Holtzman,et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy , 2015, Annals of clinical and translational neurology.

[8] L. Golbe,et al. A clinical rating scale for progressive supranuclear palsy. , 2007, Brain : a journal of neurology.